Intracavernosal Alprostadil (Caverject) for Erectile Dysfunction: A Complete Evidence-Based Guide
Introduction
When oral medications fail — and for millions of men they do — the answer may lie in a small needle and a precisely measured dose of alprostadil injected directly into the penis. It sounds intimidating. Most men, when first presented with intracavernosal injection therapy, recoil. Yet for those who follow through with training, the response is striking: over 80% of patients experienced an erection sufficient for sexual intercourse after intracavernosal injection of Caverject in pivotal clinical trials — a success rate that rivals or exceeds any other currently available ED treatment.
Caverject, the brand name for alprostadil sterile powder formulated for intracavernosal use, has been an FDA-approved treatment for erectile dysfunction since 1995. Alprostadil is the only FDA-approved agent for intracavernosal injections in the treatment of erectile dysfunction. For men who cannot take or do not respond to PDE5 inhibitors like tadalafil or sildenafil, it represents a highly effective, evidence-based alternative with three decades of real-world safety data. This article explains the science, the technique, the evidence, and everything a patient needs to know to make an informed decision.
What Is Alprostadil and How Does It Work?
Prostaglandin E1: A Natural Vasodilator
Alprostadil is a synthetic form of prostaglandin E1 (PGE1) — a naturally occurring lipid mediator derived from arachidonic acid that plays a key role in vascular regulation, inflammation, and smooth muscle tone throughout the body. In the penis specifically, PGE1 exerts powerful vasodilatory effects through a distinct molecular pathway from that of PDE5 inhibitors.
The cAMP Mechanism
Unlike PDE5 inhibitors, which work through the nitric oxide/cyclic GMP pathway and require sexual stimulation to be effective, alprostadil operates through a parallel and complementary mechanism:
- Alprostadil binds to prostaglandin E receptors (EP receptors) on cavernosal smooth muscle cells
- Receptor activation stimulates adenylate cyclase, producing cyclic AMP (cAMP)
- Elevated cAMP activates protein kinase A, causing smooth muscle relaxation and cavernosal arterial dilation
- Increased arterial inflow to the corpora cavernosa produces tumescence and rigidity
- The process does not require sexual stimulation — erection occurs through direct pharmacological action
This mechanistic independence from the NO/cGMP pathway means alprostadil is effective in men with severely compromised endothelial function — the very patients most likely to fail oral PDE5 inhibitors.
Onset and Duration
This medicine usually begins to work in about 5 to 10 minutes. You should attempt intercourse within 10 to 30 minutes after using the medicine. The erection typically lasts 30–60 minutes — the target duration for safe, effective sexual activity — after which spontaneous detumescence occurs as alprostadil is metabolized locally.
Who Is a Candidate for Intracavernosal Alprostadil?
Indications
Intracavernosal alprostadil is indicated for men with erectile dysfunction of:
- Vasculogenic etiology — arterial insufficiency, venous leak, atherosclerotic disease
- Neurogenic etiology — spinal cord injury, multiple sclerosis, diabetic neuropathy
- Post-radical prostatectomy — cavernous nerve injury from prostate cancer surgery
- Psychogenic etiology — when oral therapy is ineffective or unsuitable
- Mixed etiology — combinations of the above
- Diagnostic use — as a pharmacological erection agent during duplex Doppler ultrasound of penile vasculature
Who Should Not Use Caverject
Absolute and relative contraindications include:
- Conditions predisposing to priapism: sickle cell anemia or trait, multiple myeloma, leukemia
- Penile anatomical abnormalities: severe Peyronie’s disease with anatomical distortion incompatible with injection
- Cavernosal venous leakage: avoid use of Caverject in patients with known cavernosal venous leakage
- Anticoagulant therapy: patients on anticoagulants, such as warfarin or heparin, may have increased propensity for injection site bleeding after intracavernosal injection with Caverject
- Severe cardiovascular disease: where sexual activity is medically inadvisable
- Hypersensitivity to alprostadil or any component of the formulation
The Clinical Evidence: Efficacy Across ED Etiologies
Landmark Trial Data
In a dose-response study of 296 men, all doses of alprostadil were superior to placebo and there was a significant dose-response relation (P<0.001), resulting in higher response rates with increasing doses of alprostadil (from 2.5 to 20 μg).
The efficacy and safety of alprostadil was investigated in men with erectile dysfunction of vasculogenic, neurogenic, psychogenic, and mixed causes across three separate multi-institutional, prospective studies. These pivotal trials established alprostadil as an effective therapy with efficacy demonstrated across all major ED etiological categories.
Efficacy Summary Across Studies
| Patient Population | Response Rate | Notes |
| General ED (vasculogenic/mixed) | > 80% | Erection sufficient for intercourse |
| Post-radical prostatectomy | 60–75% | Lower due to severe nerve damage |
| Neurogenic (spinal cord injury) | 70–85% | Often responds to lower doses |
| Diabetic ED | 65–80% | Effective despite microvascular disease |
| PDE5 inhibitor non-responders | ~70% | Key indication for injection therapy |
| Psychogenic ED | > 85% | High response; psychological support recommended alongside |
Long-Term Benefits: More Than Just an Erection
Long-term intracavernosal self-injection with alprostadil improved the penile circulation, and most men reported an increase in return of spontaneous erections. This finding — that regular alprostadil injection can actually improve underlying erectile function over time — has important implications for post-prostatectomy penile rehabilitation, where early and sustained cavernosal oxygenation may reduce fibrosis and preserve erectile tissue architecture.
Dosing and Administration
Formulations Available
Caverject is available in two delivery systems:
| Formulation | Strengths Available | Reconstitution | Key Feature |
| Caverject (vial) | 5, 10, 20, 40 mcg | Bacteriostatic water for injection | Standard; cost-effective |
| Caverject Impulse | 10, 20 mcg | Pre-filled dual-chamber cartridge | Self-contained; easier preparation |
Dose Titration Protocol
Critical principle: The correct dose must be determined by a physician in-office before any home self-injection begins. The dose of Caverject must be established based on the individual needs of each patient, through careful dose identification under medical supervision. In clinical studies, patients were treated with doses ranging from 0.2 to 140 micrograms; however, since 99% of patients received doses of 60 micrograms or less, administration of more than 60 micrograms is not recommended.
Standard titration schedule:
For vasculogenic/psychogenic/mixed ED:
- Start: 2.5 mcg
- If partial response: increase to 5 mcg, then 5–10 mcg increments
- Target: lowest dose producing adequate erection lasting ≤ 60 minutes
For neurogenic ED (spinal cord injury):
- Start: 1.25 mcg (lower starting dose due to heightened sensitivity)
- Increment by 1.25 mcg → 2.5 mcg → 5 mcg increments
- Same target: adequate erection ≤ 60 minutes
Injection Technique
The injection is administered along the dorso-lateral aspect of the proximal third of the penis. Avoid visible veins. Alternate the side of the penis that is injected and the site of injection with each administration. The injection site must be cleansed with an alcohol swab.
Key technical points for patients:
- Wash hands thoroughly before preparing the injection
- Reconstitute the powder with the provided bacteriostatic water
- Inject into the side of the penis (not the top, bottom, or tip) — 3 or 9 o’clock position
- Use a 27–30 gauge, ½-inch needle — the smallest practical gauge for comfort
- Apply gentle pressure at the injection site after withdrawal
- Do not inject more than once per 24 hours
- Do not use more than 3 times per week
- Rotate injection sites to minimize fibrosis risk
Safety Profile: Managing Adverse Effects
Common Adverse Effects
Penile pain after intracavernosal administration of Caverject was reported at least once by 37% of patients in clinical studies of up to 18 months in duration. In the majority of the cases, penile pain was rated mild or moderate in intensity. Three percent of patients discontinued treatment because of penile pain.
| Adverse Effect | Incidence | Management |
| Penile pain | 37% (majority mild/moderate) | Reassurance; usually improves with ongoing use |
| Prolonged erection (4–6 hrs) | 4% | Seek medical attention promptly |
| Priapism (> 6 hrs) | 0.4% | Medical emergency — immediate treatment required |
| Penile fibrosis/nodules | 3–8% (long-term) | Reduce frequency; consider treatment pause |
| Hematoma/bruising | ~3% | Proper injection technique; pressure post-injection |
| Hypotension | Rare | Systemic absorption; sit after injection initially |
Priapism: The Critical Safety Warning
Priapism — an erection lasting longer than 4–6 hours — is the most serious complication of intracavernosal injection therapy. Prolonged ischemic priapism causes progressive cavernosal hypoxia, acidosis, and ultimately irreversible fibrosis with permanent ED if untreated.
Rule of 4 hours: Any erection lasting more than 4 hours demands immediate urological attention. Treatment involves:
- Aspiration of blood from the corpora cavernosa
- Intracavernosal injection of a sympathomimetic agent (phenylephrine is preferred)
- Surgical shunting in refractory cases
Patients must be counseled on this risk before beginning therapy and must have a clear action plan including emergency contact numbers.
Alprostadil vs. Other ED Treatments
Where Intracavernosal Injection Fits in the Treatment Hierarchy
| Treatment | Efficacy | Onset | Duration | Invasiveness | Best For |
| PDE5 inhibitors (sildenafil, tadalafil) | 65–75% | 30–60 min | 4–36 hrs | None (oral) | First-line; psychogenic/mild-moderate organic |
| Intracavernosal alprostadil | > 80% | 5–10 min | 30–60 min | Injection | PDE5 failure; neurogenic; post-prostatectomy |
| Intraurethral alprostadil (MUSE) | 30–65% | 5–10 min | 30–60 min | Suppository | Patients unable/unwilling to inject |
| Vacuum erection device | ~70% | 5–10 min | Limited by ring | Non-invasive | All etiologies; complements injection |
| Penile implant | > 90% satisfaction | Immediate | Not applicable | Surgery | Failed all other treatments |
| Trimix (alprostadil + papaverine + phentolamine) | 85–90% | 5–15 min | 30–60 min | Injection | PDE5 failure; reduced alprostadil-related pain |
Alprostadil vs. Trimix
Trimix is a standardized, compounded combination medication used for intracavernosal injection therapy. This drug comprises alprostadil, papaverine, and phentolamine, and is generally considered more effective and reliable than alprostadil alone. The effective dose of intracavernosal Trimix is typically about half the volume of alprostadil when used alone. This reduces both the cost and post-injection pain associated with alprostadil, as less PGE1 is required to achieve an equivalent erectile response.
Trimix is not FDA-approved (it is compounded) but is widely used as an alternative when alprostadil-associated penile pain is limiting or when higher doses are required.
Practical Considerations for Long-Term Use
Adherence and Dropout
Long-term adherence to injection therapy is a recognized challenge. Dropout reasons include:
- Injection anxiety — the primary reason for discontinuation in the first 3 months
- Penile pain — the most common physical reason for stopping
- Partner reluctance — the interruption of spontaneity affects couples differently
- Recovery of spontaneous function — paradoxically, some men stop because their spontaneous erections improve
- Transition to oral therapy — as treatments evolve or underlying conditions respond to management
Monitoring During Treatment
During self-injection treatment, it is recommended that the patient visit their doctor every 3 months. These follow-up visits allow assessment of injection technique, penile health (checking for fibrosis), dose optimization, and evaluation of any underlying cause progression.
Penile Rehabilitation After Prostatectomy
For men who have undergone nerve-sparing radical prostatectomy, early initiation of intracavernosal alprostadil — typically within 4–8 weeks of surgery — is a cornerstone of penile rehabilitation protocols at many centers. The goal is maintaining cavernosal oxygenation and preventing hypoxia-driven smooth muscle fibrosis during the period of nerve recovery, which may take 12–24 months. Studies support earlier and higher rates of return to spontaneous erection in men who undergo early injection rehabilitation versus those who wait.
Conclusion
Intracavernosal alprostadil (Caverject) is one of the most effective treatments available for erectile dysfunction — achieving success rates exceeding 80% across all major ED etiologies, including cases that fail oral PDE5 inhibitor therapy entirely. With three decades of clinical use, a well-characterized safety profile, and the unique ability to produce erections independently of sexual stimulation or nitric oxide pathway integrity, it occupies an essential and irreplaceable position in the urological management of ED.
The needle is the barrier for most men. The data argues strongly for overcoming it. When trained properly, the vast majority of patients report that injection therapy is far more manageable than anticipated — and the quality of erections it produces, for men who have sometimes waited years for an effective solution, is life-changing.
Your next steps if you are considering intracavernosal therapy:
- Request a referral to a urologist or sexual medicine specialist experienced in injection therapy training
- Ask whether PDE5 inhibitors have truly been optimized at maximum dose before transitioning to injection therapy
- Discuss Trimix as an alternative if penile pain with alprostadil alone is a concern
- Ensure your partner is involved in the training process — acceptance and comfort with the technique significantly improves long-term adherence
- If you have had prostate cancer surgery, ask specifically about starting penile rehabilitation within the first 1–3 months post-operatively
- Always keep the emergency priapism protocol — urologist contact number and nearest emergency room location — accessible before your first home injection